Nanomedicines: From Bench to Bedside and Beyond

Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.

[1]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[2]  Hong Wang,et al.  Complement activation associated with polysorbate 80 in beagle dogs. , 2013, International immunopharmacology.

[3]  Donald E. Mager,et al.  Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology , 2014, Pharmaceutics.

[4]  Marina A Dobrovolskaia,et al.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[6]  L. Mayer,et al.  Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. , 2001, The Journal of pharmacology and experimental therapeutics.

[7]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Shivendra V. Singh,et al.  Molecular Targets and Mechanisms of Cancer Prevention and Treatment by Withaferin A, A Naturally Occurring Steroidal Lactone , 2013, The AAPS Journal.

[9]  Sonke Svenson,et al.  Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Duan-yun Si,et al.  Validated HPLC assay of liposome-encapsulated and non-liposomal doxorubicin in plasma and its application to pharmacokinetic study , 2010 .

[11]  Celia N. Cruz,et al.  CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products , 2013, The AAPS Journal.

[12]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[13]  John W. Park,et al.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.

[14]  Man Liu,et al.  Nanomedicine Drug Development: A Scientific Symposium Entitled “Charting a Roadmap to Commercialization” , 2014, The AAPS Journal.

[15]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[16]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[17]  E. Masini,et al.  Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog , 1985, Agents and Actions.

[18]  W. Zamboni,et al.  A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents , 2013, Clinical Cancer Research.

[19]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[20]  L. Lévy,et al.  Delivering nanomedicines to patients: a practical guide. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[21]  S. Barry,et al.  Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo , 2016, Science Translational Medicine.

[22]  R. Lionberger,et al.  A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution , 2012, The AAPS Journal.